SMYD2 and hepatocellular carcinoma: In HCC and thyroid cancer, overexpression of SMYD2 is positively correlated with enlarged tumor size, more rapid lymphatic invasion, more potential tumor invasion, and higher TNM stage, as well as worsened overall rate of survival [57, 60, 63–66].